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David Martí, MD, PHD,* Miguel Rubio, MD,y Natalia Escribano, MD,z Ramón de Miguel, MD,y Ignacio Rada, MD, PHD,*
César Morís, MD, PHDxA n 85-year-old man presented with dyspneaNew York Heart Association functional classIV 4 years after implantation of a 26-mm Cor-
eValve transcatheter aortic valve (TAV) (Medtronic,
Minneapolis, Minnesota). Angiography revealedFIGURE 1 Multiplane Transesophageal Echocardiography
(Left) Homogeneous thickening of the SAPIEN XT (Edwards Lifesciences
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FIGURE 2 Operative Findings Revealing Thrombotic Material
Adhered to the 3 Aortic Cusps
Note the endothelialization of the CoreValve (Medtronic, Min-
neapolis, Minnesota) frame and the proper expansion of the
SAPIEN XT valve (Edwards Lifesciences, Irvine, California).
FIGURE 3 Pathologic Sample of a Thrombosed Leaﬂet
Masson trichrome–stained section of a thrombosed leaﬂet, with
lines of Zahn present and without ﬁbrosis or calciﬁcation within
the thrombus (magniﬁcation, 4). L ¼ leaﬂet; T ¼ thrombus.
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e152continued 15 months after the SAPIEN XT valve
implantation, and aspirin monotherapy continued
thereafter.
Two months after clopidogrel discontinuation, the
patient required 3 visits to the emergency depart-
ment with overt heart failure. Echocardiography
showed high transvalvular gradients (peak, 55 mmHg;
mean, 31 mm Hg; dimensionless valve index, 0.25),
thickened leaﬂets, and mild to moderate central
aortic regurgitation (Figure 1, Online Videos 2 and 3).
The heart team decided to perform a surgical aortic
valve replacement. Operative and pathology ﬁndings
revealed a diffuse ﬁbrin-platelet thrombus adhered
to the aortic surface on the 3 SAPIEN XT valve cusps
(Figures 2 and 3). This valve was partially denuded
and easily extracted from within the CoreValve
prosthesis. Both TAVs were explanted via alongitudinal aortotomy, and a 21-mm bioprosthesis
was sutured to the well-preserved aortic annulus.
Unfortunately, the patient died of cardiac arrest in
the postoperative period.
Valve thrombosis is a rare but increasingly recog-
nized complication of transcatheter heart valves.
Indeed, a systematic review has shown that throm-
bosis is the major cause of valve stenosis in the early
years after implantation (1). As in this case, TAV
thrombosis is usually not associated with typical
thrombus images on transesophageal echocardiogra-
phy, and operators must be cautious when handling
catheters in the vicinity of a stenotic TAV (1,2).
Balloon-expandable prostheses are sometimes
used to reduce aortic regurgitation after CoreValve
implantation (3). Our ﬁndings suggest that in this
setting, internal prosthesis endothelialization may
be delayed or incomplete, representing an addi-
tional risk factor for late thrombosis. Therefore, TAV-
in-TAV therapies with balloon-expandable valves
might require longer duration of dual-antiplatelet
therapy.
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APPENDIX For supplemental videos,
please see the online version of this paper.
